<--- Back to Details
First PageDocument Content
Medicine / Clinical medicine / Immunology / Immunosuppressants / Monoclonal antibodies / Biotechnology / Immune system / TNF inhibitor / Infliximab / Adalimumab / Disease-modifying antirheumatic drug / Etanercept
Date: 2015-06-19 09:17:18
Medicine
Clinical medicine
Immunology
Immunosuppressants
Monoclonal antibodies
Biotechnology
Immune system
TNF inhibitor
Infliximab
Adalimumab
Disease-modifying antirheumatic drug
Etanercept

TABLE OF CONTENTS INTRODUCTION 2

Add to Reading List

Source URL: www.abirisk.eu

Download Document from Source Website

File Size: 435,49 KB

Share Document on Facebook

Similar Documents

Medicine / Clinical medicine / Immunology / RTT / Autoimmune diseases / Immunosuppressants / Rheumatology / Arthritis / Disease-modifying antirheumatic drug / Infliximab / Methotrexate / Psoriatic arthritis

Provincial Drug Programs P. O. Box 2000 Charlottetown PE C1A 7N8Toll Free on PEI) Programmes provinciaux de médicaments

DocID: 1qAvE - View Document

Medicine / Clinical medicine / Immunology / Immunosuppressants / Monoclonal antibodies / Biotechnology / Immune system / TNF inhibitor / Infliximab / Adalimumab / Disease-modifying antirheumatic drug / Etanercept

TABLE OF CONTENTS INTRODUCTION 2

DocID: 1qius - View Document

Medicine / Clinical medicine / Immunology / Immunosuppressants / RTT / Autoimmune diseases / Monoclonal antibodies / Arthritis / Disease-modifying antirheumatic drug / Psoriatic arthritis / Infliximab / Rheumatoid arthritis

THE EFFECTIVENESS OF NON BIOLOGIC DMARDS AFTER ANTI TNF α INHIBITOR FAILURE DECISION SUPPORT UNIT Allan Wailoo, Jonathan Tosh School of Health and Related Research, University of Sheffield

DocID: 1pY4l - View Document

Monoclonal antibodies / Autoimmune diseases / Biotechnology / Immunosuppressants / Immunology / TNF inhibitor / Rheumatology / Adalimumab / Infliximab / Arthritis / Disease-modifying antirheumatic drug / Rheumatoid arthritis

TABLE OF CONTENTS INTRODUCTION 2

DocID: 1pESm - View Document

Health economics / Healthcare quality / Immunosuppressants / Orphan drugs / Costs / Disease-modifying antirheumatic drug / Tocilizumab / Rituximab / Quality-adjusted life year / Rheumatoid arthritis / Etanercept / TNF inhibitor

TOCILIZUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

DocID: 1pnYX - View Document